Loading…
Loading…
Incyte Corp
NASDAQ · Stock Profile · Market Cap $18.11B
Current Price
$92.24
-2.10%GoodMoat Value
$189.11
105.0% undervaluedCapital expenditures increased by 299% from FY25 to FY25.
Net Cash: 3.1B
1.0B
FY24
1.1B
FY24
4.2B
FY24
1.1B
FY25
1.2B
FY25
1.4B
FY25
5.1B
FY25
—
FY24
106M
FY24
33M
FY24
158M
FY25
405M
FY25
424M
FY25
1.3B
FY25
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
Delaware, USA
INCY's revenue grew at a 30.4% CAGR over the last 6 years.
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Run a full DCF analysis with customizable assumptions
Open DCF Calculator →Graham Number, PEG-based, and Earnings-based models
View Fair Value →This stock does not currently pay a dividend.
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
Delaware, USA